Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis by Geneva Guarin, Audrey Netzel, Karen Marie Flores, Arun Cumpelik, Ron Bose

Subjects: Get full text

Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study by Miroslawa Püsküllüoğlu, Małgorzata Pieniążek, Manuela Las-Jankowska, Joanna Streb, Marek Ziobro, Renata Pacholczak-Madej, Paulina Kilian-Van Miegem, Agnieszka Rudzińska, Aleksandra Grela-Wojewoda, Aleksandra Łacko, Michał Jarząb, Anna Polakiewicz-Gilowska

Subjects: Get full text

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis by Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cezar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Lima Barros Costa

Subjects: “…Sacituzumab govitecan…”
Get full text

A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan by Takamichi Ito, Yuka Tanaka, Dai Ogata, Haruto Nishida, Tatsushi Shiomi, Ryo Tanaka, Aya Kawaguchi, Azusa Miyashita, Satoshi Fukushima, Naoko Shojiguchi, Hiroyuki Goto, Yaei Togawa, Takahiro Kiyohara, Yoshinao Oda, Takeshi Nakahara

Subjects: Get full text

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan by Megan H. Wong, Veronica C. Jones, Wai Yu, Linda D. Bosserman, Sayeh M. Lavasani, Niki Patel, Mina S. Sedrak, Daphne B. Stewart, James R. Waisman, Yuan Yuan, Joanne E. Mortimer

Subjects: Get full text

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine by Saif Khan, Suresh Babu Jandrajupalli, Nashwa Zaki Ali Bushara, Rama Devi Patel Raja, Shadab Mirza, Kuldeep Sharma, Rajan Verma, Ashish Kumar, Mohtashim Lohani

Subjects: Get full text